1. Engholm G, Ferlay J, Christensen N, Kejs AMT, Hertzum-Larsen R, Johannesen TB, Khan S, Leinonen MK, Ólafsdóttir E, Petersen T, Schmidt LKH, Trykker H SH. NORDCAN: Cancer Incidence, Mortality, Prevalence and Survival in the Nordic Countries, Version 7.3 (08.07.2016). Association of the Nordic Cancer Registries. Danish Cancer Society Available from
http://www.ancr.nu
, accessed on 09/08/2016. 2016;2008–9.
http://www-dep.iarc.fr/NORDCAN/DK/frame.asp
. Accessed 9 Aug 2016.
2. Garland SM, Kjaer SK, Munoz N, Block SL, Brown DR, Dinubile MJ, et al. Impact and effectiveness of the quadrivalent human papillomavirus vaccine: a systematic review of 10 years of real-world experience. Clin Infect Dis. 2016;63:519–27.
3. The Danish Health and Medicines Authority. Report from the Danish Health and Medicines Authority for consideration by EMA and rapporteurs in relation to the assessment of the safety profile of HPV-Vaccine 2015.
4. The Danish Medicines Agency. Registration and monitoring of side effects.
https://laegemiddelstyrelsen.dk/en/sideeffects/side-effects-from-medicines/registration-and-monitoring/
. Accessed 28 Aug 2017.
5. Smith A, Yarwood J, Salisbury DM. Tracking mothers’ attitudes to MMR immunisation 1996-2006. Vaccine. 2007;25:3996–4002.